Table 2 Clinical features associated with positive resultsa.

From: Diagnosing hereditary cancer predisposition in men with prostate cancer

All gene univariate analysis (n = 1812)
  All gene carriers (n = 262) All gene negative (n = 1550) OR (95% CI) p value
Percentage 14.46% 85.54%   
Age at Dx (IQR) 59 (53.75, 65) 60 (54, 66) 0.99 (0.98, 1.01) 0.32
Personal history of other cancer
  Yes 126 632 1.35 (1.03, 1.75) 2.67E-02
  No 136 918   
Family history of cancer FDR onlyb
  Yes 222 1295 1.09 (0.77, 1.59) 0.631
  No 40 255   
Family history of PC FDR only
  Yes 103 582 1.08 (0.82, 1.41) 0.59
  No 159 968   
Family history of PCc
  Yes 137 780 1.08 (0.83, 1.41) 0.56
  No 125 770   
Met Hopkins FPC criteria
  Yes 46 317 0.92 (0.65, 1.28) 0.61
  No 229 1446   
>1 relative with breast, ovarian or pancreatic cancerc
  Yes 114 535 1.46 (1.12, 1.9) 5.14E-03
  No 148 1015   
>1 relative with Lynch-related cancerc
  Yes 97 475 1.33 (1.01, 1.74) 0.04
  No 165 1075   
HBOC criteria
  Yes 67 313 1.36 (1, 1.83) 1.94E-05
  No 195 1237   
Lynch criteria
  Yes 89 337 1.85 (1.39, 2.45) 1.94E-05
  No 173 1213   
Metastatic
  Yes 33 164 1.45 (0.57, 4.45) 0.47
  No 5 36   
  Missing 224 1350 1.19 (0.51, 3.51) 0.71
Gleason score
  <7 17 145   
  ≥7 106 649 1.39 (0.83, 2.47) 0.23
  Missing 139 756 1.57 (0.94, 2.76) 0.099
  1. CI confidence interval, Dx diagnosis, FDR first-degree relative, FPC familial prostate cancer, HBOC hereditary breast and ovarian cancer, OR odds ratio, PC prostate cancer.
  2. aClinical variables as reported on test requisition forms.
  3. bNonmelanoma skin cancers and unspecified cancers are excluded.
  4. cIncludes first, second, and third-degree relatives.
  5. Statistically significant values are in bold.